Tapentadol and Sleepwalking: A Case Report.
J Pharm Pract
; 35(4): 647-649, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-33622091
ABSTRACT
OBJECTIVE:
This is a case report of a patient with sleepwalking likely caused by tapentadol ER secondary to higher than the recommended dose for the treatment of pain.METHODS:
This report presents the relevant patient history, laboratory data and literature review on possible causes of this patient's sleepwalking.RESULTS:
A 39-year-old female reported sleepwalking as the dose of tapentadol increased above the recommended maximum provided in the package insert. The mechanism of action of tapentadol involving norepinephrine reuptake inhibition affecting the central nervous system, higher dosage and drug interactions with other home medications likely contributed to her sleepwalking.CONCLUSION:
This case highlights the importance of adhering to the recommended dosage of a medication and if it is clinically warranted to exceed the maximum recommended dose, the importance of diligent monitoring for any adverse effects.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
8_ODS3_consumo_sustancias_psicoactivas
Problema de saúde:
8_opioid_abuse
Assunto principal:
Sonambulismo
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
J Pharm Pract
Assunto da revista:
FARMACIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos